Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹26,619Cr
Rev Gr TTM
Revenue Growth TTM
26.29%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

KIMS
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 54.7 | 22.3 | 15.7 | 7.8 | 10.1 | 13.6 | 19.1 | 27.5 | 25.7 | 26.6 | 23.6 | 29.2 |
| 413 | 449 | 475 | 459 | 475 | 509 | 559 | 585 | 599 | 679 | 757 | 799 |
Operating Profit Operating ProfitCr |
| 28.3 | 25.9 | 27.2 | 24.3 | 25.1 | 26.1 | 28.1 | 24.2 | 24.9 | 22.1 | 21.2 | 19.9 |
Other Income Other IncomeCr | 5 | 3 | 3 | 3 | 4 | 5 | 5 | 18 | 15 | 7 | 4 | 5 |
Interest Expense Interest ExpenseCr | 5 | 9 | 9 | 12 | 16 | 18 | 20 | 26 | 27 | 33 | 45 | 57 |
Depreciation DepreciationCr | 35 | 32 | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 53 | 66 | 79 |
| 127 | 119 | 139 | 102 | 100 | 127 | 162 | 135 | 134 | 114 | 97 | 69 |
| 29 | 32 | 37 | 26 | 29 | 32 | 42 | 42 | 28 | 29 | 25 | 17 |
|
Growth YoY PAT Growth YoY% | 18.4 | 9.4 | -4.5 | -6.5 | -27.5 | 9.8 | 19.2 | 20.8 | 48.4 | -10.7 | -40.4 | -43.9 |
| 17.1 | 14.3 | 15.5 | 12.6 | 11.3 | 13.8 | 15.5 | 12.0 | 13.3 | 9.8 | 7.5 | 5.2 |
| 2.3 | 2.0 | 2.3 | 1.8 | 1.6 | 2.2 | 2.7 | 2.2 | 2.5 | 2.0 | 1.7 | 1.3 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 38.3 | 22.3 | 18.5 | 24.1 | 33.1 | 13.7 | 21.5 | 19.5 |
| 598 | 837 | 878 | 959 | 1,135 | 1,594 | 1,861 | 2,252 | 2,833 |
Operating Profit Operating ProfitCr |
| 9.9 | 8.8 | 21.8 | 27.9 | 31.2 | 27.5 | 25.5 | 25.8 | 21.9 |
Other Income Other IncomeCr | 37 | 6 | 6 | 10 | 30 | 41 | 16 | 43 | 32 |
Interest Expense Interest ExpenseCr | 83 | 46 | 40 | 33 | 16 | 31 | 47 | 90 | 161 |
Depreciation DepreciationCr | 40 | 56 | 71 | 70 | 73 | 129 | 147 | 177 | 251 |
| -20 | -15 | 141 | 279 | 457 | 485 | 460 | 558 | 413 |
| 26 | 34 | 25 | 74 | 113 | 119 | 124 | 143 | 98 |
|
| | -5.2 | 336.8 | 78.6 | 67.3 | 6.4 | -8.2 | 23.5 | -24.1 |
| -7.0 | -5.3 | 10.3 | 15.4 | 20.8 | 16.6 | 13.4 | 13.7 | 8.7 |
| -9.4 | -6.9 | 16.0 | 26.9 | 8.4 | 8.4 | 7.8 | 9.6 | 7.5 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 50 | 74 | 74 | 78 | 80 | 80 | 80 | 80 | 80 |
| -209 | 466 | 523 | 786 | 1,307 | 1,590 | 1,748 | 2,058 | 2,190 |
Current Liabilities Current LiabilitiesCr | 749 | 201 | 219 | 278 | 215 | 296 | 452 | 836 | 1,146 |
Non Current Liabilities Non Current LiabilitiesCr | 347 | 351 | 366 | 282 | 282 | 707 | 1,307 | 2,481 | 2,904 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 156 | 174 | 220 | 451 | 393 | 478 | 547 | 697 | 823 |
Non Current Assets Non Current AssetsCr | 802 | 944 | 976 | 985 | 1,514 | 2,464 | 3,304 | 5,039 | 5,802 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 |
Investing Cash Flow Investing Cash FlowCr | -64 | -110 | -125 | -354 | -412 | -547 | -753 | -1,116 |
Financing Cash Flow Financing Cash FlowCr | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 |
|
Free Cash Flow Free Cash FlowCr | 49 | 57 | 150 | 262 | 154 | -140 | -125 | -380 |
| -229.0 | -275.6 | 175.1 | 173.2 | 94.3 | 118.1 | 155.1 | 140.3 |
CFO To EBITDA CFO To EBITDA% | 161.5 | 165.4 | 82.3 | 96.0 | 62.8 | 71.5 | 81.8 | 74.3 |
| Financial Year | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 11,043 | 11,254 | 16,471 | 25,581 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 33.2 | 33.5 | 53.1 | 66.5 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 | 6.7 | 5.1 | 6.6 | 8.4 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 8.0 | 6.7 | 9.0 | 12.0 |
| 4.8 | 3.7 | 1.1 | 0.1 | 21.5 | 19.6 | 27.9 | 35.8 |
Profitability Ratios Profitability Ratios |
| 75.7 | 77.1 | 77.4 | 78.3 | 78.5 | 78.1 | 78.8 | 79.3 |
| 9.9 | 8.8 | 21.8 | 27.9 | 31.2 | 27.5 | 25.5 | 25.8 |
| -7.0 | -5.3 | 10.3 | 15.4 | 20.8 | 16.6 | 13.4 | 13.7 |
| 37.3 | 3.6 | 19.5 | 26.4 | 28.8 | 22.0 | 15.9 | 13.8 |
| 29.1 | -9.0 | 19.3 | 23.8 | 24.8 | 21.9 | 18.4 | 19.4 |
| -4.8 | -4.3 | 9.6 | 14.3 | 18.0 | 12.4 | 8.7 | 7.2 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) is one of India's largest and fastest-growing corporate healthcare providers. Headquartered in Hyderabad, Telangana, and founded in 2000 by Dr. B. Bhaskar Rao, a renowned cardiothoracic surgeon, the company has evolved from a single hospital in Nellore, Andhra Pradesh, into a pan-Indian healthcare network. KIMS is focused on delivering **affordable, high-quality tertiary and quaternary care** through a **multi-specialty, integrated model** supported by advanced technology and clinical innovation.
Listed on Indian stock exchanges since 2021, KIMS leverages a hybrid growth strategy combining **organic expansions, strategic acquisitions, and partnerships**, with a strong emphasis on **doctor equity participation, technology adoption, and scale leadership**.
---
### **Network & Scale (As of Aug 2025)**
- **25 hospitals** across 5 states: **Telangana, Andhra Pradesh, Maharashtra, Kerala, and Karnataka**.
- **Over 8,000 operational beds**, with a total network capacity expected to exceed **10,000 beds** post-expansion.
- **~1,800 incremental beds** under development across key locations, including:
- **Bangalore (Project-1 & 2):** 800 beds (combined)
- **Kondapur (Telangana):** 500 beds
- **Rajahmundry (Andhra Pradesh):** 350 beds
- Over **1,600 doctors** and **10,000+ employees** network-wide.
---
### **Clinical Capabilities & Specialties**
KIMS offers comprehensive care across **25+ specialties**, with a focus on high-complexity, capital-intensive services:
- **Cardiac Sciences**
- **Oncology** (including dedicated cancer centers in Ongole, Anantapur, and planned in Bangalore)
- **Neurosciences & Epilepsy Care**
- **Organ Transplantation** (Heart, Lung, Liver, Kidney) – **190 lung transplants in 3 years**, **national record**.
- **Orthopedics & Robotic Joint Replacements** – Acquired **Sunshine Hospitals**, South Asia’s second-largest orthopedic center with 10,000+ annual surgeries.
- **Mother & Child Care** (Cuddles brand expansion in multiple cities)
- **Gastroenterology & Transplant Hepatology**
- **Renal Sciences and Nephrology**
#### **Advanced Technology & First-in-India Procedures**
- **South Asia’s first and India’s only TULSA-PRO** center for **MRI-guided, incision-free prostate treatment** (benign prostatic hyperplasia and localized cancer).
- **Robotic Surgery Program**: KIMS-Kingsway (Nagpur) has performed **50 Da Vinci robotic-assisted surgeries**, offering **minimally invasive procedures** with faster recovery.
- **MR-Guided Focused Ultrasound (MRgFUS)** for **non-invasive treatment** of essential tremors and Parkinson’s. Achieved **100% success rate** in early patient cases.
- **Omniscient Neuro-technology brain mapping** for enhanced surgical precision in neurosurgery.
- **Elekta radiation therapy systems** worth **USD 38–40 million**, deployed across facilities to **upgrade oncology capabilities**.
---
### **Geographic Expansion Strategy**
KIMS is aggressively expanding beyond its traditional stronghold in Telangana and Andhra Pradesh to **de-risk regional concentration** and tap into underserved markets.
#### **Recent Expansions (Aug 2025)**
- **Karnataka**: Entered with **two hospitals in Bangalore (Mahadevpur & Electronic City)** with ~800 beds total. Plans to expand into **Sarjapur and northern Bangalore (750–1,000 beds)**.
- **EBITDA neutrality expected at 30–40% occupancy**, pending timely **doctor onboarding and insurance empanelment**.
- **Kerala**: Acquired **Sreechand Hospital (Kannur)** and signed O&M agreements with **Westfort Hi-Tech Hospital (Thrissur)**. Launched units in **Kollam, Kannur, and Kozhikode**.
- Future **800-bed health cities** planned in **Kochi and Kozhikode**.
- Focus on **transplant services** and **oncology** in Tier 2/3 cities.
- **Maharashtra**: Operational presence in **Nagpur, Nashik, and Thane**.
- **Sangli and Guntur** hospitals are **breakeven**, each generating **INR 17–18 crores/month**.
- Thane, Nashik, and Kollam generate **INR 5.5, 15.5, and 9 crores/monthly revenue**, respectively.
#### **O&M (Operations & Management) Model**
- Controls **P&L, clinical hiring, and operations** in partner-owned facilities.
- Operates **3 O&M hospitals** (Hyderabad, Thrissur, Sangli), with **1 more planned in Telangana**.
- Minimizes capital risk while expanding market presence.
- **Kompally hospital (Hyderabad)** under O&M with **no operational cost to KIMS**.
---
### **Strategic Initiatives**
- **Expansion into Tier 2 & 3 Cities**: Leverages lower competition, high unmet demand, and strong brand recall in Telugu-speaking regions (Andhra, Telangana, Karnataka, Maharashtra).
- **Cluster-Based Development**: Focused on creating **integrated healthcare hubs** in urban clusters (e.g., Hyderabad, Bangalore, Nagpur).
- **Digital Health & Wellness**: Investing in **telemedicine, preventive diagnostics**, and **online care platforms** to tap post-COVID wellness demand.
- **Research & Academia**:
- **KIMS Foundation & Research Centre (KFRC)** – NAC-SCRT accredited for stem cell research.
- Collaborations with **ICMR, IIPH, University of Hyderabad** on clinical trials and patient registries.
- **Leadership & Talent**:
- Appointed veteran leaders: **Dr. Nitish Shetty (Bangalore Cluster)**, **Mr. Farhaan Yaseen (Kerala Cluster)**, **Mr. Sreenath Reddy (Kerala & Karnataka)**.
- Focus on **retention of top consultants** via equity participation (>80% doctor retention since inception).